USRE34089E - Article useful for administration of pharmacologically-active substances transdermally, orally, or by means of implant - Google Patents

Article useful for administration of pharmacologically-active substances transdermally, orally, or by means of implant Download PDF

Info

Publication number
USRE34089E
USRE34089E US07/554,499 US55449990A USRE34089E US RE34089 E USRE34089 E US RE34089E US 55449990 A US55449990 A US 55449990A US RE34089 E USRE34089 E US RE34089E
Authority
US
United States
Prior art keywords
pharmacologically
plasticizer
iaddend
iadd
active agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US07/554,499
Inventor
Agis Kydonieus
Kishore R. Shah
Bret Berner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hercon Laboratories Corp
Original Assignee
Hercon Laboratories Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/847,635 external-priority patent/US4758434A/en
Application filed by Hercon Laboratories Corp filed Critical Hercon Laboratories Corp
Priority to US07/554,499 priority Critical patent/USRE34089E/en
Application granted granted Critical
Publication of USRE34089E publication Critical patent/USRE34089E/en
Assigned to FIRST NATIONAL BANK OF MARYLAND, THE reassignment FIRST NATIONAL BANK OF MARYLAND, THE SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HERCON LABORATORIES CORPORATION, A DELAWARE CORPORATION
Assigned to FIRST NATIONAL BANK OF MARYLAND, THE reassignment FIRST NATIONAL BANK OF MARYLAND, THE SECURITY AGREEMENT Assignors: HERCON LABORATORIES CORPORATION
Assigned to HERCON LABORATORIES CORPORATION reassignment HERCON LABORATORIES CORPORATION RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: FIRST NATIONAL BANK OF MARYLAND, THE
Assigned to HERCON LABORATORIES CORPORATION reassignment HERCON LABORATORIES CORPORATION RELEASE AND REASSIGNMENT OF PATENTS AS COLLATERAL Assignors: FIRST NATIONAL BANK OF MARYLAND, THE
Assigned to IBM SCHRODER BANK & TRUST COMPANY, AS AGENT reassignment IBM SCHRODER BANK & TRUST COMPANY, AS AGENT SECURITY AGREEMENT Assignors: HERCON LABORATORIES CORPORATION
Assigned to IBJ SCHRODER BANK & TRUST COMPANY, AS AGENT reassignment IBJ SCHRODER BANK & TRUST COMPANY, AS AGENT SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HEROON LABORATORIES CORPORATION
Assigned to HERCON LABORATORIES CORPORATION reassignment HERCON LABORATORIES CORPORATION PATENT RE-ASSIGNMENT AND RELEASE OF SECURITY AGREEMENT Assignors: IBJ WHITEHALL BUSINESS CREDIT CORPORATION, (F/K/A IBJ SCHRODER BUSINESS CREDIT CORPORATION, AS SUCCESSOR IN INTEREST TO IBJ SCHRODER BANK & TRUST COMPANY)
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time

Definitions

  • This invention relates broadly to articles of manufacture for administration of pharmacologically-active substances, transdermally, orally and by means of implant (e.g., subdermal implant).
  • the devices consist essentially of a vinyl chloride polymer or copolymer of vinyl chloride containing a majority of vinyl chloride monomeric units and a small amount of other vinyl monomeric units, e.g., vinyl acetate, and intimately dispersed therewith at least one of said pharmacologically-active agents and a plasticizer.
  • pharmacologically-active agents are isosorbide dinitrate, nicotine, indomethacin, clonidine, glyceryl trinitrate, guanfacine and prostaglandin.
  • Contemplated within the scope of this invention are devices for the controlled release and transdermal administration of such pharmacologically-active agents as nitroglycerine (e.g. in the treatment of conditions, e.g., angina pectoris).
  • Canadian Pat. No. 930,668 discloses a bandage for administering drugs comprised of a backing member, a pressure sensitive adhesive, and at least one reservoir disposed between the backing member and pressure sensitive adhesive.
  • the reservoir is comprised of a systemically active drug formulation confined within a wall member, the wall member being formed from a drug release rate controlling material.
  • the reservoir can be in the form of discrete microcapsules or distinct reservoir compartments or layers.
  • the reservoir can also be in the form of walled containers having one or more interior drug-containing chambers, as well as solid matrixes having a systemically active drug distributed therethrough.
  • the Canadian patent discloses a wide variety of materials which can be used to form the reservoir.
  • silicone rubbers hydrophilic polymers of monoesters of an olefinic acid, polyvinylalcohol, polyvinylacetate, plasticized polyvinylchloride, plasticized nylon, collagen, modified collagen, gelatin, and waxes such as polyethylene wax, oxidized polyethylene wax, hydrogenated castor oil and the like, with the silicone rubbers being preferred.
  • the Canadian patent does to contain any examples showing the use of plasticized polyvinyl chloride, and does not show the use of a PVC plastisol.
  • Example 6 at column 15, lines 5-30 of U.S. Pat. No. 3,921,636 relates to a polyvinyl chloride resin containing plasticizer and prednisolone disodium phosphate thusly:
  • a drug delivery device for the controlled, oral administration of water-soluble prednisolone is prepared as follows: first, a plurality of drug reservoirs comprising porous, discrete particles of polymerized poly(vinyl chloride) of about 100 microns diameter are prepared by mixing 100 g of suspension grade poly(vinyl chloride) resin with 50 g of octyl diphenyl phosphate and 10 g of predinisolone disodium phosphate at room temperature into a sticky, wet mass. Next, the temperature of the mixture is raised to 80° C. for about 3 to 7 minutes, while stirring, to form dry, free flowing, discrete drug reservoirs.
  • the reservoirs are uniformly dispersed through a matrix by mixing 50 g of reservoirs containing the prednisolone with 140 g of polydimethylsiloxane, 10 g of silicone oil, and 0.5 g of stannous octoate. After mixing the ingredients, the mixture is charged into pill molds and allowed to cure for 30 minutes. Oral administration of the resulting device yields a controlled essentially constant rate of release of prednisolone phosphate to the gastrointenstinal tract to give a more uniform blood level of premisolone over a longer period of time than is achieved when prednisolone alcohol is administered by standard prior art pills.”
  • PVC polyvinyl chloride
  • Polyvinyl chloride is never used alone, but is always mixed with other ingredients before being processed.
  • Polyvinyl chloride appeared initially to be an unpromising resin because of its thermal instability and high rigidity.
  • PVC was then discovered to form a rubber-like material when dissolved hot in high boiling solvents known as plasticizers and cooled to room temperature.
  • PVC is now available in a number of different physical forms and types, and its manufacture depends on the form desired.
  • PVC is available as a vinyl latex, a dispersion resin, or a general purpose resin.
  • PVC latexes are true colloidal dispersions of submicrometer particles in water, stabilized by a surfactant system, and need plasticizers in order to form a continuous film.
  • the PVC in vinyl latex is manufactured by emulsion polymerization.
  • Dispersion resins are produced by emulsion polymerization and are mixed with plasticizers to form a colloidal dispersion. Such dispersions are known as plastisols and are easily handled and readily pourable. When heated to a temperature of about 148° to 177° C., the plastisol is transformed to a homogeneous melt which, upon cooling to below 50° C., results in a tough flexible product.
  • the PVC resins made by emulsion polymerization are hard spheres of particle size between about 0.05 and 20 microns, such as between 1 and 20 microns. They do not have the ability to absorb plasticizers. Therefore, a mixture containing, for exmaple, 30% plasticizer and 70 PVC resin, produces a flowable liquid, known a plastisol.
  • General purpose PVC resins are made by mass and suspensin polymerization process, and comprise the largest amount of PVC resins produced, such as at least 80% of all PVC resins, and are used chiefly to make so-called 100% vinyl products by a variety of molding and extrusion techniques. Resins intended for flexible applications should have good uptake of plasticizer in a dry blending operation and contain more than 25% of a plasticizer system.
  • PVC compounds that contain less than 25% plasticizers are referred to as semirigid compounds:
  • the PVC resins manufactured by suspension and bulk polymerization are 50 to 200, such as 100 to 150 microns in diameter, and are like sponges They are capable of absorbing large amounts of plasticizers, so that even 50% plasticizer, 50% PVC resin composition would result in a non-flowing, solid material.
  • pharmacologically-active agents such as isosorbide dinitrate, nicotine, indomethacin, clonidine, glyceryl trinitrate, guanfacine, and prostaglandin directly from a plastisol resin layer in which the pharmacological
  • This invention also enables the administration of a pharmacologically-active agent, such as isosorbide dimitrate, nicotine, indomethacin, clonidine, glyceryl trinitrate, guanfacine, and prostaglandin to be achieved through an article of manufacture, e.g., a transdermal delivery device requiring contact with a relatively smaller area of a patient's tissue, such as the epidermis in the case of a transdermal delivery device.
  • a pharmacologically-active agent such as isosorbide dimitrate, nicotine, indomethacin, clonidine, glyceryl trinitrate, guanfacine, and prostaglandin
  • this invention is directed to an article of manufacture incorporating a polyvinyl chloride resin plastisol monolayer for administration of pharmacologically-active agents transdermally, orally or by means of subdermal implant to a patient requiring treatment for a condition such as, for example, angina pectoris (in the case of the use of such materials as nitroglycerin).
  • pharmacologically-active agents such as isosorbide dinitrate, nicontine, indomethacin, clonidine, glyceryl trinitrate, guanfacine and prostaglandin can be homogeneously dispersed in high concentrations in a plastisol of an emulsion polymerized polyvinyl chloride resin and plasticizer; the composition is fused into a solid layer and the layer is applied onto the tissue of a patient (either transdermally, orally or subdermally) whereby the pharmacologically-active agent is absorbed either (i) through the patient's skin or (ii) through the patient's internal membranes or (iii) directly ionto the circulation system.
  • pharmacologically-active agents such as isosorbide dinitrate, nicontine, indomethacin, clonidine, glyceryl trinitrate, guanfacine and prostaglandin
  • a preferred embodiment comprises a multilayer adhesive bandage device incorporating a plastisol monolayer containing homogeneously dispoersed pharmacologically-active agents, e.g., isosorbide dinitrate, nicotine, indomethacin, clonidine, glyceryl trinitrate, guanfacine and prostaglandin.
  • pharmacologically-active agents e.g., isosorbide dinitrate, nicotine, indomethacin, clonidine, glyceryl trinitrate, guanfacine and prostaglandin.
  • FIG. 1 is a cross-sectional view of a preferred pharmacologically-active agent delivery device in accordance with this invention.
  • FIG. 2 is a plan view of a strip of material in accordance with this invention viewed from the surface which is applied to the patient's skin.
  • FIG. 3 is a plan view of material in accordance with this invention viewed from the surface away from the surface which is applied to the patient's skin.
  • FIG. 4 is an enlarged sectional schematic view of a specific embodiment of the invention; a transdermal device for controlled release of a pharmacologically-active agent from a plastisol monolayer through a membrane transdermally.
  • FIG. 5 is an enlarged sectional schematic view of another embodiment of the invention where there is no membrane separating the plastisol monolayer from the epidermis and whereby pharmacologically-active agent is transported from the plastisol transdermally into the patient.
  • FIG. 6 is a perspective view of a roll of material in accordance with this invention.
  • FIG. 7 is a graph of tensile strength (PSI) versus percent resin containing either of isosorbide dinitrate, nicotine, indomethacin, clonidine, glyceryl trinitrate or guanfacine, specifically as described herein in the description of Examples VIII-XIII, infra.
  • PSI tensile strength
  • FIG. 8 is graph showing release rate of pharmacologically-active agent (in micrograms per square centimeter per hour) versus percent resin, individually, for isosorbide dinitrate, nicotine, indomethacin, clonidine, glyceryl trinitrate or guanfacine specifically in relationship to Examples XIV-XIX, infra.
  • FIG. 9 is a graph of plasma concentration (picograms per milliliter) versus time detected in a human subject during the clinical study concerning the composition of matter consisting of polyvinyl chloride resin, dioctyl adipate plasticizer and prostaglandin as specifically set forth in Example XX, infra.
  • FIG. 10 is a graph showing the effective decrease in diastolic blood pressure of the human subject observed during the period of patch application as specifically set forth in Example XX.
  • FIG. 11 is a graph of delivery of nitroglycerine versus time resulting from the use of the formulation of Example XXI.
  • FIG. 12 is the infrared spectrum of ADMEX® 760 as used in Examples II-XIX.
  • transdermal devices containing various pharmacologically-active agents including, but not limited to, indomethacin having the structure: ##STR1## guanfacine having the structure: ##STR2## clonidine having the structure: ##STR3## nicotine having the structure: ##STR4## isosorbide dinitrate having the structure: ##STR5## glyceryl trinitrate and prostaglandin (e.g., methyl ( ⁇ ) -[11a, 5z and 5E), 13E, 16R (and 16S)]-16-ethenyl-11,16 dihydroxy-9-oxoprosta-5, 13-dien-1-oate. It will be understood that other embodiments may be employed within the spirit and scope of this invention.
  • the articles of our invention are useful for transdermal, oral and subdermal administration of pharmacologically-active substances and comprise a solid vinyl plastisol layer (consisting essentially of polyvinyl chloride and a plasticizer) for contacting a patient's skin or other membrane.
  • the vinyl plastisol layer contains from about 20 up to about 70% by weight of a polyvinyl chloride resin which consists essentially of a vinyl chloride polymer containing, predominantly or completely repeating vinyl chloride monomeric units and in an amount of less than about 10% other repeating vinyl units, e.g., repeating vinyl acetate units; from about 20% up to about 70% by weight of the composition of one or more plasticizers; from about 0.5 up to about 35% by weight of the total composition of a pharmacologically-active substance, such as isosorbide dinitrate, nicotine, indomethacin, clonidine, glyceryl trinitrate, guanfacine or prostaglandin and optionally other excipients, such as materials which will accelerate transdermal penetration as exemplified hereinafter. .Iadd.As one example of the use of a pharmacologically-active substance, nitroglycerin can be present in an amount of about 20-35%. .Iaddend.
  • the reservoir layers of this invention are relatively weak and less than 1500 psi, (FIG. 7), highly flexible and soft materials.
  • the flexible vinyl films of commerce are considerably stronger materials exhibiting tensile strengths of the order of 1,500 to 5,000 psi.
  • the polyvinyl chloride resin content of the commercially useful and available flexible vinyl films ranges from 50 to 75%. Such materials do not have adequate drug permeating characteristics to serve as suitable drug delivery reservoirs.
  • the device 1 includes a solid plastisol monolayer 2 which is composed of or comprises resin, plasticizer and a pharmacologically-active agent as set forth supra.
  • a formulation for layer 2 may comprise from about .[.2.]. .Iadd.20 .Iaddend.up to about 70% by weight of the vinyl resin, from about 20 up to about 70% by weight of plasticizer composition, from about 0.5 up to about 35% by weight of pharmacologically-active agent and the remainder being other excipients, such as materials which will enhance skin penetration.
  • the substance 1-dodecylhexahydro-2H-azepin-2-one also known as AZONE® having the structure: ##STR6## acts as both a plasticizer and as an agent which enhances transdermal penetration of pharmacologically-active agents such as isosorbide dinitrate, indomethacin and the like as set forth supra.
  • N,N-diethyltoluamide having the structure: ##STR7## acts in the same manner as AZONE®.
  • a specific formulation for layer 2 comprises about 54% polyvinyl chloride (PVC) resin, about 36% dioctyl phthalate (DOP) plasticizer and 10% nitroglycerin.
  • PVC polyvinyl chloride
  • DOP dioctyl phthalate
  • the articles of the present invention including the transdermal devices as well as subdermal implants and orally ingested articles of the present invention comprise a polyvinyl chloride plastisol layer in a fused state and a pharmacologically-active agent uniformly dispersed in the fused layer which may be referred to as a reservoir for the pharmacologically-active agent.
  • the polyvinyl chloride reservoir in the reset invention is prepared from polyvinyl chloride resin and a primary plasticizer for the resin.
  • the polyvinyl chloride resin employed in the practice of the present invention is that which is specifically used in preparing PVC plastisols, namely, PVC resins which are made by the well known emulsion polymerization process, which are hard spheres of particle size between 0.05 and 20 microns, such as between 1 and 20 microns, for example, between 1 and 5 microns, or between 0.05 and 1 micron, and which do not have the ability to absorb plasticizers to any great extent. Instead, the plasticizer wets the resin particles at room temperature and only then very slowly penetrates and solvates the resin.
  • PVC resins when mixed with plasticizers, such as a mixture of 30% primary plasticizer, 70% PVC resin, give a flowable liquid known as plastisol which can then be fused at, for example, approximately 250° F. for approximately 30 seconds to provide a solid polymer layers.
  • the PVC resin employed in the present invention is in contrast to the general purpose PVC resins which are produced by suspension or bulk polymerization and which are used in calendering and extrusion processes, which are 50 to 200 microns, such as 100 to 150 microns in diameter, and are like sponges.
  • the civil purpose resins are capable of absorbing large amounts of plasticizers so that even a 50% DOP and 50% PVC resin would result in a non-flowing solid material.
  • the molecular weight of the PVC resins employed in the present invention preferably is a weight average molecular weight between 80,000 and 250,000, such as a weight average molecular weight of 123,000.
  • a suitable polyvinyl chloride resin is one sold by Occidental Chemical Co. under the designation FPC 6338 containing about 96% vinyl chloride monomer units of about 4% vinyl acetate monomer units.
  • the polyvinyl chloride resin can be a copolymer containing preferably at least 90% by weight vinyl chloride monomer units, such as a copolymer based on vinyl chloride and vinyl acetate.
  • the polyvinyl chloride resin generally is present in the layer in an amount of 10 to 75 weight percent, preferably 20 to 70 weight percent, based on the total weight of the vinyl plastisol composition.
  • the primary plasticizer which is employed in the present invention can be dioctylphthalate (DOP), benzylbutylphthalate, tri-2-ethylhexylmalaete, dioctyl adipate, epoxidized soybean oil, polymeric adipate plasticizers, which are polymers of adipic acid with a monomer, such as propylene plycol, and for example can be obtained under the designation Drapex 334F from Witco Chemical Corp., or any other known primary plasticizer for PVC which is biologically acceptable.
  • DOP dioctylphthalate
  • benzylbutylphthalate tri-2-ethylhexylmalaete
  • dioctyl adipate epoxidized soybean oil
  • polymeric adipate plasticizers which are polymers of adipic acid with a monomer, such as propylene plycol, and for example can be obtained under the designation Drapex 3
  • polyester adipates examples include glutarates and sebacates.
  • polyester adipate (P)P-644 polyester adipate (P)P-644
  • polyester glutarate (P)P-530 polyester glutarate (P)P-530;
  • polyester glutarate (P)P-550 polyester glutarate (P)P-550;
  • polyester glutarate (P)P-7035 polyester glutarate (P)P-7035
  • polyester glutarate (P)P-7035M polyester glutarate (P)P-7035M
  • polyester plasticizers which are polyesters of (i) 1,4-terephthalic acid and/or 1,2-phthalic acid with (ii) ethylene glycol or 1,3-propylene glycol having molecular weights in the range of 4000-10,000 are preferred.
  • Another preferred plasticizer which also acts as a skin penetrating enhancer for pharmacologically-active drugs which are intended for transdermal delivery from devices such as those set forth in FIGS. 1, 5 and 6 is the compound having the structure: ##STR8## known as AZONE® marketed by the Nelson Research and Development Co.
  • the composition comprising PVC and the compound having the structure: ##STR9## is a novel composition of matter.
  • plasticizers can be used.
  • the term "primary plasticizer” as used herein refers to a plasticizer which can be used alone to effect plasticization and is highly compatible with PVC at high concentrations, such as, for example, 150 parts per hundred. Primary plasticizers are contrasted with “secondary plasticizers” which, because of limited compatibility with PVC, cannot be used alone. See, Kirk-Othmer Encyclopedia of Chemical Technology, Volume 23, 3rd Edition, especially pages 913 and 914 for a discussion of primary and secondary plasticizers, which is incorporated by reference herein.
  • the primary plasticizer generally is present in an amount of 20 to 85 weight percent, preferably 20 to 70% based on the total weight of the vinyl plastisol layer.
  • the PVC plastisol may optionally contain other additives or "excipients" useful in the practice of this invention, for example, material which enhance skin penetrated of the pharmacologically-active substances (e.g., 1,6-hexanediol and n-decyloleate) and thickeners, e.g., silica (preferably "fumed” silica, for example, AEROSIL® in an amount of from 1-6% of the layer).
  • pharmacologically-active substances e.g., 1,6-hexanediol and n-decyloleate
  • thickeners e.g., silica (preferably "fumed” silica, for example, AEROSIL® in an amount of from 1-6% of the layer).
  • the blended plastisol containing for example, PVC, DOP and nitroglycerin is then coated at a rate of about 36 ounces/yd 2 on a backing, and then fused into solid plastisol layer 2.
  • the backing may be a single layer of drug impermeable plastic or other material, but is preferably composed of two layers 3 and 4.
  • Layer 3 may be MYLAR® (polyester produced from ethylene glycol and phthalic anhydride) about 0.5 mils thick
  • layer 4 may be PVC, about 4 mils thick.
  • the backing 3,4 substantially blocks loss of drug from the plastisol layer 2other than in the direction of the surface which, in use, will contact the patient's skin.
  • the blended plastisol which is coated on the backing can be fused into a homogeneous solid by heating it for a short period, such as 15 to 30 seconds, at a temperature of, for example, 250° to 280° F.
  • a plastisol to form solid layer 2 enables to be formed by using a low temperature for a short period of time and provides conditions which do not affect the stability of the pharmacologically-active agents.
  • a strip of solid plastisol layer 2 and backing 3,4 is then tonded to a pressure-sensitive adhesive layer 5 which in turn is provided with a non-adhesive backing 6 such as one made of plastic, moisture-proof fabric, aluminum foil, etc.
  • the entire surface intended for skin contact is preferably covered with a release paper 7 or the like which is removed to expose surfaces of the adhesive layer 5 and drug containing plastisol layer 2 for application to the patient's skin.
  • FIG. 2 shows a plan view of a strip of material 20 during the stage of manufacture at which a strip of the plastisol 2 (backing 3,4 not shown) has been applied to the adhesive tape (backing 6 not shown).
  • a plastisol strip preferably about one inch (1") in width is applied on a two and one-half inch (21/2") wide pressure-sensitive adhesive strip.
  • FIG. 3 shows a plan view of a strip of the material 30 in accordance with this invention; spaced lines 31 may be embossed or printed on the surface away from skin contact so that the patient may conveniently measure out and cut off the proper amount of tape device to provide the prescribed daily dosage.
  • the pharmacologically-active agent e.g., nitroglycerin
  • a segment 1" long cut from the longer tape resulting in an approximately one square inch (1 sq.
  • the components of embodiment 33 are backing layer 34, a reservoir layer 35 that contains supplies of percutaneous absorption enhancer and pharmacologically-active substance, such as indomethacin, a diffusion membrane layer 36 and a peripheral ring 37 of contact adhesive.
  • the diffusion membrane layer may be composed of a polymer, such as copolymer of ethylene and methyl acrylate with the methyl acrylate being in the range of 2-90% by weight of the polymer, or blends of such copolymer with low density polyethylene, high density polyethylene or linear low density polyethylene.
  • the contact adhesive component of embodiment 33 is in the form of a peripheral ring.
  • backing layer 34 may also be a semi-permeable membrane.
  • the contact adhesive may be attached directly to the membrane 36, in which case the adhesive is selected so that it is permeable to the active agent.
  • the basil surface from which the pharmacologically-active substance and enhancer e.g., AZONE® is transferred to the skin is defined by diffusion membrane layer 36.
  • the backing layer is not flat but instead forms a pocket or cavity in which the reservoir layer is held. The outer edge of the backing layer is sealed to the peripheral ring of the contact adhesive as more specifically set forth in U.S. Pat No. 4,379,454 issued on Apr.
  • an article within the contemplation of our invention need not have a matrix as illustrated in FIG. 5 wherein the backing 61 totally surrounds the PVC-plastisol-plasticizer matrix 62 and is firmly in place as with an adhesive on the skin 63.
  • the device of the invention may conveniently be provided in the form of a tape roll 50 from which daily dosage requirements may be clipped by the patient.
  • the device is capable of application to humans or other animals capable of usefully absorbing drugs through the skin.
  • a plastisol was formed by mixing 54% of a polyvinyl chloride resin sold under the designation FPC 6338 by Occidental Chemical Corp. and having a particle size between 1 and 5 microns, 36% DPO, and 10% nitroglycerin.
  • the product was coated onto 1 mil polyester (MYLAR) film and cured at 280° F.
  • the final product consisted of 8.8% nitroglycerin, 31.8% DOP, 47.8% FPC 6338, 11.6% polyester. This product can be used for delivery of nitroglycerin percutaneously.
  • Fused plastisol drug reservoirs having variable PVC plasticizer ratios were prepared by heating cast films of the drug containing plastisols at 290° F. for 60 seconds.
  • the drugs used were isosorbide dinitrate (ISDN) and nicotine.
  • AZONE® having the structure: ##STR10## (registered trademark of the Nelson Research and Development Co.)
  • the films, thus prepared, were optically transparent.
  • FIG. 12 is the infrared spectrum ADMEX® of 760.
  • the stress-strain properties of the films were determined employing standard procedures using Instron Universal Testing Instrument.
  • the ability of the reservoir to release the drug evaluated by measuring the dissololution rate of the drug in fluid medium (receptor phase) when a known surface area of drug reservoir film was exposed to an excess of the receptor at 31° C.
  • the dissolution rate studies were conducted a Franz diffusion cell.
  • the receptor phase for the nicotine study was pH 4.0 citric acid buffer solution (an aqueous solution containing 1.2% citric acid and 1.1% disodium hydrogen phosphate), and that for the ISDN study was an aqueous solution containing 20% polyethylene glycol 400.
  • the dissolution rate of the drug was calculated from the change in concentration of the drug in the receptor phase at different time intervals.
  • the nicotine and ISDN concentrations were determined by ultraviolet spectroscopy and high pressure liquid chromatographic procedures, respectively.
  • FIG. 7 shows tensile versus percent resin for each of the above formulations.
  • the curve indicated by reference numeral 70 is the curve for clonidine.
  • the curve indicated by reference numeral 71 is the curve for guanfacine.
  • the curve indicated by reference numeral 72 is the curve for .[.indocin.]. .Iadd.indomethacin.Iaddend..
  • the curve indicated by reference numeral 73 is the curve for nicotine.
  • the curve indicated by reference numeral 74 is the curve for isosorbide dinitrate.
  • the curve indicated by reference numeral 75 is the curve for glyceryl trinitrate.
  • FIG. 8 is a graph showing release rate in micrograms per square centimeter per hour versus percent resin.
  • the curve indicated by reference numeral 80 is the curve for nicotine.
  • the curve indicated by reference numeral 81 is the curve for clonidine.
  • the curve indicated by reference numeral 82 is the curve for guanfacine.
  • the curve indicated by reference numeral 83 is the curve for isosorbide dinitrate.
  • the curve indicated by reference numeral 84 is the curve for indomethacin.
  • the curve indicated by reference numeral 85 is the curve for glyceryl trinitrate.
  • Prostaglandin American Cyanamid Co. Methyl ( ⁇ )-[11 ⁇ , 5z (and 5E), 13E, 16R (and 16S)]ethenyl-11,16-dihydroxy-9-oxoprosta-5, 13-dien-11-oate (an analog of Prostaglandin E 2 ).
  • the curve indicated by reference numeral 90 shows plasma concentration in picograms per ml versus time in hours.
  • the units of pressure are mmHg and the units of time are in hours.
  • the patch delivered adequate nitroglycerin through skin of human subjects to provide a concentration of 0.1 to 0.2 ng/ml in the blood plasma for a period of 3 days as set forth in FIG. 11.
  • the graph indicated by reference numeral 111 is a graph of delivery of glyceryl trinitrate in nanograms/ml versus time (in hours).
  • Formulations containing 7.5% ISDN, and 0, and 32% AZONE® respectively were tested in vivo on monkeys. Each formulation was tested on two monkeys for six consecutive days. The patches were firmly placed on the shaved upper innerarm each morning and were left in place for eight hours. For each test condition blood samples of approximately 3-4 ml were withdrawn from an indwelling catheter inserted into the saphenous vein. Blood samples were drawn at 0 (prior to patch application), 4 and 8 hours after dosing. The eight-hour samples was drawn before the patches were removed. The plasma component was immediately separated from the blood by centrifugation at 1200 rpm for 5 minutes, and frozen at -20° C. The samples were then extracted to determine concentrations of ISDN and its metabolites Isosorbide 5-mononitrate (5-ISMN) and Isosorbide 2-Mononitrate (2-ISMN).
  • 5-ISMN Isosorbide 5-mononitrate
  • 2-ISMN Isosorbide 2-Mononitrate
  • the site of application was washed with dilute alcohol and inspected visually. Any changes in the condition of the skin (such as erythema or edema) was scored according to the Draze Scoring System. This inspection was repeated 30 minutes and again before next patch application.
  • a maximum of 43.8% ng/ml of plasma ISDN was obtained from 2patches with a total surface area of 12.5 cm 2 .
  • the data did not suggest that there was a linear increase of plasma level with surface area of patch. In general, doubling the patch surface area more than doubled the plasma level, for ISDN as well as the metabolites.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Described is an article of manufacture useful for administration of pharmacologically-active substances, transdermally, orally or by means of subdermal implant comprising a solid vinyl plastisol layer for contacting a patient's tissue, internally or externally, the layer containing from about 20 up to about 70% by weight of a polyvinyl chloride resin or a polyvinyl chloride-polyvinyl acetate copolymer containing a minor proportion of vinyl acetate; from about 20-70% plasticizer composition, from about 0.5 up to 35% of pharmacologically-active substance such as isosorbide dinitrate, nicotine, clonidine, guanfacine, indomethacin, glyceryl trinitrate and prostaglandin and optionally excipients. Also described is the novel plasticizer-polyvinyl chloride composition of matter comprising 1-dodecylhexahydro-2H-azepin-2-one and polyvinyl chloride resin taken together with a pharmacologically-active substance .[.whereint he.]. .Iadd.wherein the .Iaddend.1-dodecylhexahydro-2H-azepin-2-one not only acts as a plasticizer but also acts as a penetration enhancer (through tissue) for the pharmacologically-active substance.

Description

BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates broadly to articles of manufacture for administration of pharmacologically-active substances, transdermally, orally and by means of implant (e.g., subdermal implant). The devices consist essentially of a vinyl chloride polymer or copolymer of vinyl chloride containing a majority of vinyl chloride monomeric units and a small amount of other vinyl monomeric units, e.g., vinyl acetate, and intimately dispersed therewith at least one of said pharmacologically-active agents and a plasticizer. Examples of pharmacologically-active agents are isosorbide dinitrate, nicotine, indomethacin, clonidine, glyceryl trinitrate, guanfacine and prostaglandin. Contemplated within the scope of this invention are devices for the controlled release and transdermal administration of such pharmacologically-active agents as nitroglycerine (e.g. in the treatment of conditions, e.g., angina pectoris).
2. The Prior Art
Many prior art articles of manufacture have been disclosed for controlled release delivery of various drugs including transdermal delivery of nitroglycerin. In general, however, available commercial devices and indeed devices published in the prior art are limited with respect to rate of delivery of pharmacologically-active substance.
Canadian Pat. No. 930,668 discloses a bandage for administering drugs comprised of a backing member, a pressure sensitive adhesive, and at least one reservoir disposed between the backing member and pressure sensitive adhesive. The reservoir is comprised of a systemically active drug formulation confined within a wall member, the wall member being formed from a drug release rate controlling material. The reservoir can be in the form of discrete microcapsules or distinct reservoir compartments or layers. The reservoir can also be in the form of walled containers having one or more interior drug-containing chambers, as well as solid matrixes having a systemically active drug distributed therethrough. The Canadian patent discloses a wide variety of materials which can be used to form the reservoir. Among the materials mentioned are silicone rubbers, hydrophilic polymers of monoesters of an olefinic acid, polyvinylalcohol, polyvinylacetate, plasticized polyvinylchloride, plasticized nylon, collagen, modified collagen, gelatin, and waxes such as polyethylene wax, oxidized polyethylene wax, hydrogenated castor oil and the like, with the silicone rubbers being preferred. The Canadian patent does to contain any examples showing the use of plasticized polyvinyl chloride, and does not show the use of a PVC plastisol.
Similarly, Zaffaroni, U.S. Pat. No. 3,921,636 issued on Nov. 25, 1975 discloses a drug delivery device for administering a drug at a controlled rate for a prolonged period of time comprising a plurality of reservoirs containing drug distributed through a matrix. The reservoirs and the matrix are formed of materials permeable to passage of the drug. The rate of drug permeation from the reservoir is lower than the rate of permeation through the matrix so that release from the reservoir is the drug release rate controlling step. Thus, Example 6, at column 15, lines 5-30 of U.S. Pat. No. 3,921,636 relates to a polyvinyl chloride resin containing plasticizer and prednisolone disodium phosphate thusly:
"A drug delivery device for the controlled, oral administration of water-soluble prednisolone is prepared as follows: first, a plurality of drug reservoirs comprising porous, discrete particles of polymerized poly(vinyl chloride) of about 100 microns diameter are prepared by mixing 100 g of suspension grade poly(vinyl chloride) resin with 50 g of octyl diphenyl phosphate and 10 g of predinisolone disodium phosphate at room temperature into a sticky, wet mass. Next, the temperature of the mixture is raised to 80° C. for about 3 to 7 minutes, while stirring, to form dry, free flowing, discrete drug reservoirs. The reservoirs are uniformly dispersed through a matrix by mixing 50 g of reservoirs containing the prednisolone with 140 g of polydimethylsiloxane, 10 g of silicone oil, and 0.5 g of stannous octoate. After mixing the ingredients, the mixture is charged into pill molds and allowed to cure for 30 minutes. Oral administration of the resulting device yields a controlled essentially constant rate of release of prednisolone phosphate to the gastrointenstinal tract to give a more uniform blood level of premisolone over a longer period of time than is achieved when prednisolone alcohol is administered by standard prior art pills."
Furthermore, as is well known, polyvinyl chloride (PVC) is never used alone, but is always mixed with other ingredients before being processed. Polyvinyl chloride appeared initially to be an unpromising resin because of its thermal instability and high rigidity. PVC, however, was then discovered to form a rubber-like material when dissolved hot in high boiling solvents known as plasticizers and cooled to room temperature. PVC is now available in a number of different physical forms and types, and its manufacture depends on the form desired. Thus, PVC is available as a vinyl latex, a dispersion resin, or a general purpose resin. PVC latexes are true colloidal dispersions of submicrometer particles in water, stabilized by a surfactant system, and need plasticizers in order to form a continuous film. The PVC in vinyl latex is manufactured by emulsion polymerization.
Dispersion resins are produced by emulsion polymerization and are mixed with plasticizers to form a colloidal dispersion. Such dispersions are known as plastisols and are easily handled and readily pourable. When heated to a temperature of about 148° to 177° C., the plastisol is transformed to a homogeneous melt which, upon cooling to below 50° C., results in a tough flexible product. The PVC resins made by emulsion polymerization are hard spheres of particle size between about 0.05 and 20 microns, such as between 1 and 20 microns. They do not have the ability to absorb plasticizers. Therefore, a mixture containing, for exmaple, 30% plasticizer and 70 PVC resin, produces a flowable liquid, known a plastisol.
General purpose PVC resins are made by mass and suspensin polymerization process, and comprise the largest amount of PVC resins produced, such as at least 80% of all PVC resins, and are used chiefly to make so-called 100% vinyl products by a variety of molding and extrusion techniques. Resins intended for flexible applications should have good uptake of plasticizer in a dry blending operation and contain more than 25% of a plasticizer system. PVC compounds that contain less than 25% plasticizers are referred to as semirigid compounds: The PVC resins manufactured by suspension and bulk polymerization are 50 to 200, such as 100 to 150 microns in diameter, and are like sponges They are capable of absorbing large amounts of plasticizers, so that even 50% plasticizer, 50% PVC resin composition would result in a non-flowing, solid material.
SUMMARY OF THE INVENTION
It is an object of the present invention to provide an article of manufacture which offers enhanced delivery capability of pharmacologically-active agents over prior commercial devices (transdermal devices, articles used to orally administer pharmacologically-active agents and subdermal implants used to administer subdermally pharmacologically-active agents) by providing an article capable of efficaciously administering pharmacologically-active agents such as isosorbide dinitrate, nicotine, indomethacin, clonidine, glyceryl trinitrate, guanfacine, and prostaglandin directly from a plastisol resin layer in which the pharmacologically-active agent is incorporated in relatively high concentrations, e.g , from 0.5 up to 35%.
This invention also enables the administration of a pharmacologically-active agent, such as isosorbide dimitrate, nicotine, indomethacin, clonidine, glyceryl trinitrate, guanfacine, and prostaglandin to be achieved through an article of manufacture, e.g., a transdermal delivery device requiring contact with a relatively smaller area of a patient's tissue, such as the epidermis in the case of a transdermal delivery device.
Thus, this invention is directed to an article of manufacture incorporating a polyvinyl chloride resin plastisol monolayer for administration of pharmacologically-active agents transdermally, orally or by means of subdermal implant to a patient requiring treatment for a condition such as, for example, angina pectoris (in the case of the use of such materials as nitroglycerin). In particular, it has been found that pharmacologically-active agents such as isosorbide dinitrate, nicontine, indomethacin, clonidine, glyceryl trinitrate, guanfacine and prostaglandin can be homogeneously dispersed in high concentrations in a plastisol of an emulsion polymerized polyvinyl chloride resin and plasticizer; the composition is fused into a solid layer and the layer is applied onto the tissue of a patient (either transdermally, orally or subdermally) whereby the pharmacologically-active agent is absorbed either (i) through the patient's skin or (ii) through the patient's internal membranes or (iii) directly ionto the circulation system.
A preferred embodiment comprises a multilayer adhesive bandage device incorporating a plastisol monolayer containing homogeneously dispoersed pharmacologically-active agents, e.g., isosorbide dinitrate, nicotine, indomethacin, clonidine, glyceryl trinitrate, guanfacine and prostaglandin.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a cross-sectional view of a preferred pharmacologically-active agent delivery device in accordance with this invention.
FIG. 2 is a plan view of a strip of material in accordance with this invention viewed from the surface which is applied to the patient's skin.
FIG. 3 is a plan view of material in accordance with this invention viewed from the surface away from the surface which is applied to the patient's skin.
FIG. 4 is an enlarged sectional schematic view of a specific embodiment of the invention; a transdermal device for controlled release of a pharmacologically-active agent from a plastisol monolayer through a membrane transdermally.
FIG. 5 is an enlarged sectional schematic view of another embodiment of the invention where there is no membrane separating the plastisol monolayer from the epidermis and whereby pharmacologically-active agent is transported from the plastisol transdermally into the patient.
FIG. 6 is a perspective view of a roll of material in accordance with this invention.
FIG. 7 is a graph of tensile strength (PSI) versus percent resin containing either of isosorbide dinitrate, nicotine, indomethacin, clonidine, glyceryl trinitrate or guanfacine, specifically as described herein in the description of Examples VIII-XIII, infra.
FIG. 8 is graph showing release rate of pharmacologically-active agent (in micrograms per square centimeter per hour) versus percent resin, individually, for isosorbide dinitrate, nicotine, indomethacin, clonidine, glyceryl trinitrate or guanfacine specifically in relationship to Examples XIV-XIX, infra.
FIG. 9 is a graph of plasma concentration (picograms per milliliter) versus time detected in a human subject during the clinical study concerning the composition of matter consisting of polyvinyl chloride resin, dioctyl adipate plasticizer and prostaglandin as specifically set forth in Example XX, infra.
FIG. 10 is a graph showing the effective decrease in diastolic blood pressure of the human subject observed during the period of patch application as specifically set forth in Example XX.
FIG. 11 is a graph of delivery of nitroglycerine versus time resulting from the use of the formulation of Example XXI.
FIG. 12 is the infrared spectrum of ADMEX® 760 as used in Examples II-XIX.
DETAILED DESCRIPTION OF THE INVENTION
The invention is described herein with respect to preferred embodiments including transdermal devices containing various pharmacologically-active agents including, but not limited to, indomethacin having the structure: ##STR1## guanfacine having the structure: ##STR2## clonidine having the structure: ##STR3## nicotine having the structure: ##STR4## isosorbide dinitrate having the structure: ##STR5## glyceryl trinitrate and prostaglandin (e.g., methyl (±) -[11a, 5z and 5E), 13E, 16R (and 16S)]-16-ethenyl-11,16 dihydroxy-9-oxoprosta-5, 13-dien-1-oate. It will be understood that other embodiments may be employed within the spirit and scope of this invention.
The articles of our invention are useful for transdermal, oral and subdermal administration of pharmacologically-active substances and comprise a solid vinyl plastisol layer (consisting essentially of polyvinyl chloride and a plasticizer) for contacting a patient's skin or other membrane. The vinyl plastisol layer contains from about 20 up to about 70% by weight of a polyvinyl chloride resin which consists essentially of a vinyl chloride polymer containing, predominantly or completely repeating vinyl chloride monomeric units and in an amount of less than about 10% other repeating vinyl units, e.g., repeating vinyl acetate units; from about 20% up to about 70% by weight of the composition of one or more plasticizers; from about 0.5 up to about 35% by weight of the total composition of a pharmacologically-active substance, such as isosorbide dinitrate, nicotine, indomethacin, clonidine, glyceryl trinitrate, guanfacine or prostaglandin and optionally other excipients, such as materials which will accelerate transdermal penetration as exemplified hereinafter. .Iadd.As one example of the use of a pharmacologically-active substance, nitroglycerin can be present in an amount of about 20-35%. .Iaddend.
It has now been found that the release rate of an active agent, which is uniformly dispersed in the vinyl plastisol layer, is critically dependent upon the proportion of the PVC resin in the composition; and the release follows a bell shaped curve (FIG. 8), the maximum occurring in the range of 30 to 50% PVC content. This is an unexpected finding, which has not hitherto been known. Such a release behavior permits tailoring of release rates of an agent from the matrix.
The reservoir layers of this invention are relatively weak and less than 1500 psi, (FIG. 7), highly flexible and soft materials. In contrast, the flexible vinyl films of commerce are considerably stronger materials exhibiting tensile strengths of the order of 1,500 to 5,000 psi. The polyvinyl chloride resin content of the commercially useful and available flexible vinyl films ranges from 50 to 75%. Such materials do not have adequate drug permeating characteristics to serve as suitable drug delivery reservoirs.
Referring to FIG. 1, the device 1 includes a solid plastisol monolayer 2 which is composed of or comprises resin, plasticizer and a pharmacologically-active agent as set forth supra.
A formulation for layer 2 may comprise from about .[.2.]. .Iadd.20 .Iaddend.up to about 70% by weight of the vinyl resin, from about 20 up to about 70% by weight of plasticizer composition, from about 0.5 up to about 35% by weight of pharmacologically-active agent and the remainder being other excipients, such as materials which will enhance skin penetration. We have found that the substance 1-dodecylhexahydro-2H-azepin-2-one (also known as AZONE® having the structure: ##STR6## acts as both a plasticizer and as an agent which enhances transdermal penetration of pharmacologically-active agents such as isosorbide dinitrate, indomethacin and the like as set forth supra. By the same token, N,N-diethyltoluamide having the structure: ##STR7## acts in the same manner as AZONE®.
Thus, for example, for a device suitable in the treatment of angina pectoris, a specific formulation for layer 2 comprises about 54% polyvinyl chloride (PVC) resin, about 36% dioctyl phthalate (DOP) plasticizer and 10% nitroglycerin. To prepare layer 2, the PVC and DOP are first blended. Due to the explosive character of the drug, dispersion of the nitroglycerin into the resulting PVC/plasticizers plastisol is then carried out under controlled conditions.
The articles of the present invention including the transdermal devices as well as subdermal implants and orally ingested articles of the present invention comprise a polyvinyl chloride plastisol layer in a fused state and a pharmacologically-active agent uniformly dispersed in the fused layer which may be referred to as a reservoir for the pharmacologically-active agent. The polyvinyl chloride reservoir in the reset invention is prepared from polyvinyl chloride resin and a primary plasticizer for the resin.
The polyvinyl chloride resin employed in the practice of the present invention is that which is specifically used in preparing PVC plastisols, namely, PVC resins which are made by the well known emulsion polymerization process, which are hard spheres of particle size between 0.05 and 20 microns, such as between 1 and 20 microns, for example, between 1 and 5 microns, or between 0.05 and 1 micron, and which do not have the ability to absorb plasticizers to any great extent. Instead, the plasticizer wets the resin particles at room temperature and only then very slowly penetrates and solvates the resin. These PVC resins when mixed with plasticizers, such as a mixture of 30% primary plasticizer, 70% PVC resin, give a flowable liquid known as plastisol which can then be fused at, for example, approximately 250° F. for approximately 30 seconds to provide a solid polymer layers. The PVC resin employed in the present invention is in contrast to the general purpose PVC resins which are produced by suspension or bulk polymerization and which are used in calendering and extrusion processes, which are 50 to 200 microns, such as 100 to 150 microns in diameter, and are like sponges. Thus, the genial purpose resins are capable of absorbing large amounts of plasticizers so that even a 50% DOP and 50% PVC resin would result in a non-flowing solid material. The molecular weight of the PVC resins employed in the present invention preferably is a weight average molecular weight between 80,000 and 250,000, such as a weight average molecular weight of 123,000. A suitable polyvinyl chloride resin is one sold by Occidental Chemical Co. under the designation FPC 6338 containing about 96% vinyl chloride monomer units of about 4% vinyl acetate monomer units. Thus, the polyvinyl chloride resin can be a copolymer containing preferably at least 90% by weight vinyl chloride monomer units, such as a copolymer based on vinyl chloride and vinyl acetate.
The polyvinyl chloride resin generally is present in the layer in an amount of 10 to 75 weight percent, preferably 20 to 70 weight percent, based on the total weight of the vinyl plastisol composition.
The primary plasticizer which is employed in the present invention can be dioctylphthalate (DOP), benzylbutylphthalate, tri-2-ethylhexylmalaete, dioctyl adipate, epoxidized soybean oil, polymeric adipate plasticizers, which are polymers of adipic acid with a monomer, such as propylene plycol, and for example can be obtained under the designation Drapex 334F from Witco Chemical Corp., or any other known primary plasticizer for PVC which is biologically acceptable.
The other examples of polyester adipates, glutarates and sebacates are:
polyester adipate (P)P-644;
polyester glutarate (P)P-530;
polyester glutarate (P)P540;
polyester glutarate (P)P-550;
polyester glutarate (P)P-7035;
polyester glutarate (P)P-7035M;
polyester glutarate (P)P-7046;
polyester glutarate (P)P-7092; and
polyester sebacate (P)P-1070
manufactured by the C. P. Hall Co., 7300 S. Central Avenue, Chicago, Ill. 60638. Other preferred plasticizers are those which are known as "phthalate" plasticizers, for example, ADMEX® 760 which is a high molecular weight (MW=8000) phthalte plasticizer manufactured by the Sherex Division of Nuodex Inc. In general, polyester plasticizers which are polyesters of (i) 1,4-terephthalic acid and/or 1,2-phthalic acid with (ii) ethylene glycol or 1,3-propylene glycol having molecular weights in the range of 4000-10,000 are preferred.
Another preferred plasticizer which also acts as a skin penetrating enhancer for pharmacologically-active drugs which are intended for transdermal delivery from devices such as those set forth in FIGS. 1, 5 and 6 is the compound having the structure: ##STR8## known as AZONE® marketed by the Nelson Research and Development Co. The composition comprising PVC and the compound having the structure: ##STR9## is a novel composition of matter.
Mixtures of known plasticizers can be used. The term "primary plasticizer" as used herein refers to a plasticizer which can be used alone to effect plasticization and is highly compatible with PVC at high concentrations, such as, for example, 150 parts per hundred. Primary plasticizers are contrasted with "secondary plasticizers" which, because of limited compatibility with PVC, cannot be used alone. See, Kirk-Othmer Encyclopedia of Chemical Technology, Volume 23, 3rd Edition, especially pages 913 and 914 for a discussion of primary and secondary plasticizers, which is incorporated by reference herein.
The primary plasticizer generally is present in an amount of 20 to 85 weight percent, preferably 20 to 70% based on the total weight of the vinyl plastisol layer.
The PVC plastisol may optionally contain other additives or "excipients" useful in the practice of this invention, for example, material which enhance skin penetrated of the pharmacologically-active substances (e.g., 1,6-hexanediol and n-decyloleate) and thickeners, e.g., silica (preferably "fumed" silica, for example, AEROSIL® in an amount of from 1-6% of the layer).
With reference to FIG. 1, the blended plastisol containing for example, PVC, DOP and nitroglycerin is then coated at a rate of about 36 ounces/yd2 on a backing, and then fused into solid plastisol layer 2. The backing may be a single layer of drug impermeable plastic or other material, but is preferably composed of two layers 3 and 4. Layer 3 may be MYLAR® (polyester produced from ethylene glycol and phthalic anhydride) about 0.5 mils thick, and layer 4 may be PVC, about 4 mils thick. The backing 3,4 substantially blocks loss of drug from the plastisol layer 2other than in the direction of the surface which, in use, will contact the patient's skin.
The blended plastisol which is coated on the backing can be fused into a homogeneous solid by heating it for a short period, such as 15 to 30 seconds, at a temperature of, for example, 250° to 280° F. The use of a plastisol to form solid layer 2 enables to be formed by using a low temperature for a short period of time and provides conditions which do not affect the stability of the pharmacologically-active agents.
A strip of solid plastisol layer 2 and backing 3,4 is then tonded to a pressure-sensitive adhesive layer 5 which in turn is provided with a non-adhesive backing 6 such as one made of plastic, moisture-proof fabric, aluminum foil, etc.
When not in use, the entire surface intended for skin contact is preferably covered with a release paper 7 or the like which is removed to expose surfaces of the adhesive layer 5 and drug containing plastisol layer 2 for application to the patient's skin.
FIG. 2 shows a plan view of a strip of material 20 during the stage of manufacture at which a strip of the plastisol 2 ( backing 3,4 not shown) has been applied to the adhesive tape (backing 6 not shown). For the preferred device for the controlled administration of pharmacologically-active agent e.g., indomethacin, isosorbide dinitrate, nicotine, clonidine, glyceryl trinitrate, guanfacine or prostaglandin, a plastisol strip preferably about one inch (1") in width is applied on a two and one-half inch (21/2") wide pressure-sensitive adhesive strip.
FIG. 3 shows a plan view of a strip of the material 30 in accordance with this invention; spaced lines 31 may be embossed or printed on the surface away from skin contact so that the patient may conveniently measure out and cut off the proper amount of tape device to provide the prescribed daily dosage. For a device for administering the pharmacologically-active agent, e.g., nitroglycerin, for example a segment 1" long cut from the longer tape (resulting in an approximately one square inch (1 sq. in.) of active surface against the the patient's skin) will provide a dosage of about 17 mg/24 hours; this is to be an enhanced rate of delivery compared with commercially available transdermal drug delivery devices and also will provide the patient with a bandage device having a surface area much smaller than found in previously available devices.
Referring to FIG. 4, the components of embodiment 33 are backing layer 34, a reservoir layer 35 that contains supplies of percutaneous absorption enhancer and pharmacologically-active substance, such as indomethacin, a diffusion membrane layer 36 and a peripheral ring 37 of contact adhesive. The diffusion membrane layer may be composed of a polymer, such as copolymer of ethylene and methyl acrylate with the methyl acrylate being in the range of 2-90% by weight of the polymer, or blends of such copolymer with low density polyethylene, high density polyethylene or linear low density polyethylene. The contact adhesive component of embodiment 33 is in the form of a peripheral ring. Optionally, backing layer 34 may also be a semi-permeable membrane. Neither the pharmacologically-active agent, e.g., isosorbide dinitrate nor enhancer passes through ring 37 and it therefore need not be permeable to those compositions. Optionally, the contact adhesive may be attached directly to the membrane 36, in which case the adhesive is selected so that it is permeable to the active agent. Secondly, the basil surface from which the pharmacologically-active substance and enhancer (e.g., AZONE® is transferred to the skin is defined by diffusion membrane layer 36. The backing layer is not flat but instead forms a pocket or cavity in which the reservoir layer is held. The outer edge of the backing layer is sealed to the peripheral ring of the contact adhesive as more specifically set forth in U.S. Pat No. 4,379,454 issued on Apr. 12, 1983, the disclosure of which is incorporated herein by reference. Similarly, an article within the contemplation of our invention need not have a matrix as illustrated in FIG. 5 wherein the backing 61 totally surrounds the PVC-plastisol-plasticizer matrix 62 and is firmly in place as with an adhesive on the skin 63.
As shown in FIG. 6, the device of the invention may conveniently be provided in the form of a tape roll 50 from which daily dosage requirements may be clipped by the patient.
The device is capable of application to humans or other animals capable of usefully absorbing drugs through the skin.
Other embodiments of our invention are those useful in, for example, U.S. Pat. Nos. 4,573,996 and 4,573,995 issued on Mar. 4, 1986, the specifications for which are incorporated by reference herein.
EXAMPLE I
A plastisol was formed by mixing 54% of a polyvinyl chloride resin sold under the designation FPC 6338 by Occidental Chemical Corp. and having a particle size between 1 and 5 microns, 36% DPO, and 10% nitroglycerin. The product was coated onto 1 mil polyester (MYLAR) film and cured at 280° F. The final product consisted of 8.8% nitroglycerin, 31.8% DOP, 47.8% FPC 6338, 11.6% polyester. This product can be used for delivery of nitroglycerin percutaneously.
EXAMPLES II-XIX FUSED PLASTISOL DRUG RESERVOIR EXAMPLES
Fused plastisol drug reservoirs having variable PVC: plasticizer ratios were prepared by heating cast films of the drug containing plastisols at 290° F. for 60 seconds. The drugs used were isosorbide dinitrate (ISDN) and nicotine. AZONE® having the structure: ##STR10## (registered trademark of the Nelson Research and Development Co.) and ADMEX® 760 (which is a high molecular weight (MW=8000) phthalate plasticizer manufactured by the Sherex Division of Nuodex Inc.) were used as primary plasticizers in the case of the ISDN and the nicotine reservoirs, respectively. The films, thus prepared, were optically transparent. FIG. 12 is the infrared spectrum ADMEX® of 760.
The stress-strain properties of the films were determined employing standard procedures using Instron Universal Testing Instrument. The ability of the reservoir to release the drug evaluated by measuring the dissololution rate of the drug in fluid medium (receptor phase) when a known surface area of drug reservoir film was exposed to an excess of the receptor at 31° C. The dissolution rate studies were conducted a Franz diffusion cell. The receptor phase for the nicotine study was pH 4.0 citric acid buffer solution (an aqueous solution containing 1.2% citric acid and 1.1% disodium hydrogen phosphate), and that for the ISDN study was an aqueous solution containing 20% polyethylene glycol 400. The dissolution rate of the drug was calculated from the change in concentration of the drug in the receptor phase at different time intervals. The nicotine and ISDN concentrations were determined by ultraviolet spectroscopy and high pressure liquid chromatographic procedures, respectively.
EXAMPLES II-VII
In the following formulations .[.(A-F.]. (.Iadd.A-E .Iaddend.in each of Examples II-VII), the following terms having the following meanings as now given:
______________________________________                                    
ISDN:      Isosorbide dinitrate having the structure:                     
            ##STR11##                                                     
AZONE:     The compound having the structure:                             
            ##STR12##                                                     
6338:      A vinyl chloride acetate copolymer                             
           having a vinyl acetate content of 4.0-4.5%                     
           manufactured by the Occidental Chemical                        
           Corporation.                                                   
ADMEX:     A high molecular weight                                        
           (MW = 8000) phthalate                                          
           plasticizer manufactured by the Sherex                         
           Division of Nuodex Inc.                                        
Nicotine:  The compound having the structure:                             
            ##STR13##                                                     
Indomethacin:                                                             
           The compound having the structure:                             
            ##STR14##                                                     
Clonidine: The compound having the structure:                             
            ##STR15##                                                     
GTN:       Glyceryl trinitrate.                                           
Guan.:     Guanfacine having the structure:                               
            ##STR16##                                                     
DOP:       Dioctyl phthalate.                                             
HG:        1,6-Hexylene glycol.                                           
Cer 140:   "Ceraphyl 140" being n-decyl oleate.                           
______________________________________
EXAMPLE II 
______________________________________                                    
ISDN FORMULATIONS                                                         
"A"          "B"      "C"      "D"    "E"                                 
______________________________________                                    
ISDN    15.0%    15.0%    15.0%  15.0%  15.0%                             
AZONE   59.5%    51.0%    42.5%  34.0%  25.5%                             
6338    25.5%    34.0%    42.5%  51.0%  59.5%                             
______________________________________
EXAMPLE III 
______________________________________                                    
NICOTINE FORMULATIONS                                                     
"A"          "B"      "C"      "D"    "E"                                 
______________________________________                                    
Nicotine                                                                  
        30.0%    30.0%    30.0%  30.0%  30.0%                             
ADMEX   49.0%    42.0%    35.0%  28.0%  21.0%                             
6338    21.0%    28.0%    35.0%  42.0%  49.0%                             
______________________________________
EXAMPLE IV 
______________________________________                                    
INDOMETHACIN FORMULATIONS                                                 
       "A"   "B"      "C"      "D"    "E"                                 
______________________________________                                    
Indomethacin                                                              
         15.0%   15.0%    15.0%  15.0%  15.0%                             
AZONE    25.5%   34.0%    42.5%  51.0%  55.0%                             
6338     59.5%   51.0%    42.5%  34.0%  30.0%                             
______________________________________
EXAMPLE V 
______________________________________                                    
CLONIDINE FORMULATIONS                                                    
"A"          "B"      "C"      "D"    "E"                                 
______________________________________                                    
Clonidine                                                                 
        20.0%    20.0%    20.0%  20.0%  20.0%                             
ADMEX   60.0%    55.0%    50.0%  45.0%  41.0%                             
6338    20.0%    25.0%    30.0%  35.0%  44.0%                             
______________________________________
EXAMPLE VI 
______________________________________                                    
GTN FORMULATIONS                                                          
"A"          "B"      "C"      "D"    "E"                                 
______________________________________                                    
GTN      8.0%     8.0%     8.0%   8.0%   8.0%                             
ADMEX   62.0%    53.0%    46.0%  39.0%  32.0%                             
6338    30.0%    39.0%    46.0%  53.0%  60.0%                             
______________________________________
EXAMPLE VII 
______________________________________                                    
GUANFACINE FORMULATIONS                                                   
"A"          "B"      "C"      "D"    "E"                                 
______________________________________                                    
Guan,   30.0%    30.0%    30.0%  30.0%  30.0%                             
DOP     25.0%    21.0%    18.0%  14.0%  10.0%                             
HG      12.5%    12.5%    12.5%  12.5%  12.5%                             
Cer 140 12.5%    12.5%    12.5%  12.5%  12.5%                             
6338    20.0%    24.0%    27.0%  31.0%  35.0%                             
______________________________________                                    
 NOTE:                                                                    
 The hexylene glycol enhances the permeability transdermally of the       
 guanfacine. The Cer 140 adjusts the activity of the guanfacine in the    
 reservoir.
EXAMPLES VIII-XIII
In the following examples, the following terms have meanings as given herein:
______________________________________                                    
ISDN:      Isosorbide dinitrate having the structure:                     
            ##STR17##                                                     
Nicotine:  The compound having the structure:                             
            ##STR18##                                                     
Indomethacin:                                                             
           The compound having the structure:                             
            ##STR19##                                                     
Clonidine: The compound having the structure:                             
            ##STR20##                                                     
GTN:       Glyceryl trinitrate.                                           
Guan.:     Guanfacine having the structure:                               
            ##STR21##                                                     
______________________________________
FIG. 7 shows tensile versus percent resin for each of the above formulations. The curve indicated by reference numeral 70 is the curve for clonidine. The curve indicated by reference numeral 71 is the curve for guanfacine. The curve indicated by reference numeral 72 is the curve for .[.indocin.]. .Iadd.indomethacin.Iaddend.. The curve indicated by reference numeral 73 is the curve for nicotine. The curve indicated by reference numeral 74 is the curve for isosorbide dinitrate. The curve indicated by reference numeral 75 is the curve for glyceryl trinitrate.
EXAMPLE VIII 
______________________________________                                    
ISDN                                                                      
% Resin      Tensile Strength                                             
______________________________________                                    
25.5          57.21                                                       
34.0         144.09                                                       
42.5         399.54                                                       
51.0         663.81                                                       
59.5         1077.53                                                      
______________________________________
EXAMPLE IX 
______________________________________                                    
NICOTINE                                                                  
% Resin      Tensile Strength                                             
______________________________________                                    
21.0          54.22                                                       
28.0         125.51                                                       
35.0         204.39                                                       
42.0         300.57                                                       
49.0         671.30                                                       
______________________________________
EXAMPLE X 
______________________________________                                    
INDOMETHACIN                                                              
% Resin      Tensile Strength                                             
______________________________________                                    
30.0          99.63                                                       
34.0         162.00                                                       
42.5         495.00                                                       
51.0         764.00                                                       
59.5         1447.00                                                      
______________________________________
EXAMPLE XI 
______________________________________                                    
CLONIDINE                                                                 
% Resin      Tensile Strength                                             
______________________________________                                    
20.0         118.36                                                       
25.0         228.70                                                       
30.0         308.99                                                       
35.0         487.65                                                       
44.0         440.16                                                       
______________________________________
EXAMPLE XII 
______________________________________                                    
GTN                                                                       
% Resin      Tensile Strength                                             
______________________________________                                    
30.0          17.53                                                       
39.0          74.90                                                       
46.0         116.43                                                       
53.0         738.85                                                       
60.0         1339.02                                                      
______________________________________
EXAMPLE XIII 
______________________________________                                    
GUAN                                                                      
% Resin      Tensile Strength                                             
______________________________________                                    
20.0          84.83                                                       
24.0         128.40                                                       
27.0         180.50                                                       
31.0         131.50                                                       
35.0         203.21                                                       
______________________________________
EXAMPLES XIV-XIX
In the following examples, the following terms have meanins as set forth below:
______________________________________                                    
ISDN:      Isosorbide dinitrate having the structure:                     
            ##STR22##                                                     
Nicotine:  The compound having the structure:                             
            ##STR23##                                                     
Indomethacin:                                                             
           The compound having the structure:                             
            ##STR24##                                                     
Clonidine: The compound having the structure:                             
            ##STR25##                                                     
GTN:       Glyceryl trinitrate.                                           
Guan.:     Guanfacine having the structure:                               
            ##STR26##                                                     
______________________________________
EXAMPLE XIV 
______________________________________                                    
ISDN                                                                      
       % Resin                                                            
              Release                                                     
______________________________________                                    
       25.5   91.66                                                       
       34.0   108.90                                                      
       42.5   93.50                                                       
       51.0   65.71                                                       
       59.5   50.29                                                       
______________________________________
EXAMPLE XV 
______________________________________                                    
NICOTINE                                                                  
       % Resin                                                            
              Release                                                     
______________________________________                                    
       21.0    40.76                                                      
       28.0   122.78                                                      
       35.0   218.25                                                      
       42.0   243.55                                                      
       49.0   216.18                                                      
______________________________________
EXAMPLE XVI 
______________________________________                                    
INDOMETHACIN                                                              
       % Resin                                                            
              Release                                                     
______________________________________                                    
       30.0   36.14                                                       
       34.0   87.01                                                       
       42.5   68.75                                                       
       51.0   24.49                                                       
       59.5    8.65                                                       
______________________________________
EXAMPLE XVII 
______________________________________                                    
CLONIDINE                                                                 
       % Resin                                                            
              Release                                                     
______________________________________                                    
       20.0   103.67                                                      
       25.0   108.22                                                      
       30.0   80.85                                                       
       35.0   82.18                                                       
       44.0   62.81                                                       
______________________________________
EXAMPLE XVIII 
______________________________________                                    
GTN                                                                       
       % Resin                                                            
              Release                                                     
______________________________________                                    
       30.0   41.91                                                       
       39.0   48.54                                                       
       46.0   42.63                                                       
       53.0   46.02                                                       
       60.0   35.81                                                       
______________________________________
EXAMPLE XIX 
______________________________________                                    
GUAN                                                                      
       % Resin                                                            
              Release                                                     
______________________________________                                    
       20.0   31.72                                                       
       24.0   56.85                                                       
       27.0   63.06                                                       
       31.0   88.41                                                       
       35.0   165.82                                                      
______________________________________
FIG. 8 is a graph showing release rate in micrograms per square centimeter per hour versus percent resin. The curve indicated by reference numeral 80 is the curve for nicotine. The curve indicated by reference numeral 81 is the curve for clonidine. The curve indicated by reference numeral 82 is the curve for guanfacine. The curve indicated by reference numeral 83 is the curve for isosorbide dinitrate. The curve indicated by reference numeral 84 is the curve for indomethacin. The curve indicated by reference numeral 85 is the curve for glyceryl trinitrate.
EXAMPLE XX Transdermal Delivery of Prostaglandin from Drug Reservoir Human Clinical Study
I Drug: Prostaglandin (American Cyanamid Co.) Methyl (±)-[11α, 5z (and 5E), 13E, 16R (and 16S)]ethenyl-11,16-dihydroxy-9-oxoprosta-5, 13-dien-11-oate (an analog of Prostaglandin E2).
II. Pharmacological Activity: Antihypertensive
III. Patch Formula:
______________________________________                                    
PVC Resin         59.7%                                                   
Dioctyl Adipate   38.2%                                                   
50% Prostaglandin  2.1%                                                   
in Dioctyl Adipate                                                        
______________________________________
IV. Results:
A. The Drug Concentration up to 500 pg/ml was detected in a human subject. (FIG. 9).
B. Effective decrease in diastolic blood pressure of the human subject was observed during the period of patch application (FIG. 10).
The curve indicated by reference numeral 90 shows plasma concentration in picograms per ml versus time in hours. The curve indicated in FIG. 10 by reference numeral 101 shows mean decrease in sitting diastolic blood pressure following administration of the subject patch formula to normal subjects in a cross over study (sample size=15). The units of pressure are mmHg and the units of time are in hours.
EXAMPLE XXI Transdermal Delivery of Nitroglycerin from Drug Reservoir-Human Clinical Study
Drug: Nitroglycerin (Glyceryl trinitrate)
Pharmacological Activity: Vasodilator
Patch Formulation:
______________________________________                                    
Ingredient         Percentage                                             
______________________________________                                    
Nitroglycerin      9.6%                                                   
Dioctyl Phthalate  76.8%                                                  
PVC Resin          9.6%                                                   
Aerosil (Fumed Silica)                                                    
                   4.0%                                                   
______________________________________
Results
The patch delivered adequate nitroglycerin through skin of human subjects to provide a concentration of 0.1 to 0.2 ng/ml in the blood plasma for a period of 3 days as set forth in FIG. 11. The graph indicated by reference numeral 111 is a graph of delivery of glyceryl trinitrate in nanograms/ml versus time (in hours).
EXAMPLE XXII
In Vivo Transdermal Delivery of Isosorbide Dinitrate (ISDN)-from Drug Reservoir
I. Patch Formula:
______________________________________                                    
ISDN (50% on Latose)                                                      
                    15%                                                   
PVC Resin           30%                                                   
AZONE ®         32%                                                   
Isopropyl Myristate 20%                                                   
Aerosil (Fumed Silica)                                                    
                     3%                                                   
______________________________________
II. Pharmacological Activity: Vasodilator
III. Test Protocol:
Formulations containing 7.5% ISDN, and 0, and 32% AZONE® respectively were tested in vivo on monkeys. Each formulation was tested on two monkeys for six consecutive days. The patches were firmly placed on the shaved upper innerarm each morning and were left in place for eight hours. For each test condition blood samples of approximately 3-4 ml were withdrawn from an indwelling catheter inserted into the saphenous vein. Blood samples were drawn at 0 (prior to patch application), 4 and 8 hours after dosing. The eight-hour samples was drawn before the patches were removed. The plasma component was immediately separated from the blood by centrifugation at 1200 rpm for 5 minutes, and frozen at -20° C. The samples were then extracted to determine concentrations of ISDN and its metabolites Isosorbide 5-mononitrate (5-ISMN) and Isosorbide 2-Mononitrate (2-ISMN).
Upon removal of the patches, the site of application was washed with dilute alcohol and inspected visually. Any changes in the condition of the skin (such as erythema or edema) was scored according to the Draze Scoring System. This inspection was repeated 30 minutes and again before next patch application.
IV. Results:
The mean plasma ISDN and metabolite results for the patches are shown in Table I. An increase of 300% to 400% in plasma ISDN concentration was observed for patches containing 32% AZONE®.
A maximum of 43.8% ng/ml of plasma ISDN was obtained from 2patches with a total surface area of 12.5 cm2. However, the data did not suggest that there was a linear increase of plasma level with surface area of patch. In general, doubling the patch surface area more than doubled the plasma level, for ISDN as well as the metabolites.
              TABLE I                                                     
______________________________________                                    
8 HOURS IN VIVO RESULTS OF                                                
ISDN PATCHES ON MONKEYS                                                   
AVERAGE CONCENTRATION (ng/ml)                                             
% AZONE ®                                                             
          No. Patches*                                                    
                      ISDN    5 ISMN  2 ISMN                              
______________________________________                                    
 0        1            3.46   12.75    3.05                               
          2           19.39   55.52   12.67                               
12        1            6.08   23.56    4.64                               
          2           30.23   68.43   17.11                               
32        1           14.14   42.01    9.75                               
          2           43.85   87.85   23.75                               
______________________________________                                    
 *Patch size was 6.25 cm.sup.2.

Claims (31)

What is claimed is:
1. A device for the controlled release and delivery to .[.human.]. tissue of a pharmacologically-active agent comprising a solid vinyl plastisol layer comprising by weight from about 30 up to about 50% polyvinyl chloride resin; from about 20 up to about 70% of plasticizer and from about 0.5 up to about 35% of said pharmacologically-active substance which when a surface of said layer is in contact with a tissue either exterior to the human epidermis or subdermally or in contact with a tissue of an animal to be treated with said pharmacologically-active agent, said pharmacologically-active agent is absorbed into and through said tissue and thence into circulatory system of said animal, said pharmacologically-active agent being uniformly dispersed in said plastisol layer in an amount such that an effective amount of said pharmacologically-active agent is absorbed into said animal in a prescribed period of time.
2. The device of claim wherein .Iadd.at least one .Iaddend.control .[.membranes.]. .Iadd.membrane .Iaddend.for secondary control of release .[.are.]. .Iadd.is .Iaddend.attached on one or both sides of said device.
3. The device of claim 1 wherein the plasticizer is a polymeric plasticizer.
4. The device of claim 1 wherein the plasticizer is a monomeric plasticizer.
5. The .[.article.]. .Iadd.device .Iaddend.wherein the plasticizer is dioctyl phthalate.
6. The .[.article.]. .Iadd.device .Iaddend.wherein the polymeric plasticizer is a polyphthalate.
7. The .[.article.]. .Iadd.device .Iaddend.of claim 3 wherein the polymeric plasticizer is epoxidized soybean oil.
8. The .[.article.]. .Iadd.device .Iaddend.of claim 2 wherein the polyvinyl chloride is present in an amount of about 30-50%, the plasticizer is present in an amount of about 30-60% and the pharmacologically-active agent is present in an amount of about 0.5-35%.
9. The .[.article.]. .Iadd.device .Iaddend.of claim 1 in the form of an elongated tape.
10. The .[.article.]. .Iadd.device .Iaddend.of claim 9 wherein said plastisol layer comprises polyvinyl chloride resin, a polymeric plasticizer or a monomeric plasticizer and a pharmacologically-active agent selected from the group consisting of isosorbide dinitrate, nicotine, indomethacin clonidine, glyercyl trinitrate, guanfacine and prostaglandin.
11. The .[.article.]. .Iadd.device .Iaddend.of claim 10 wherein said polyvinyl chloride is present in an amount of about 30-50%, said plasticizer is present in an amount of about 30-60% and said pharmacologically-active agent is present in an amount of from about 0.5 to about 35%.
12. The .[.article.]. .Iadd.device .Iaddend.of claim 11 wherein the pharmacologically-active agent is nitroglycerin and the nitroglycerin is present in an amount of about 20-35%.
13. The .[.article.]. .Iadd.device .Iaddend.of claim 11 wherein said tape is provided with indicia indicating the length of a segment of said tape which is adequate to administer a prescribed dosage of said pharmacologically-active substance.
14. The .[.article.]. .Iadd.device .Iaddend.of claim 9 in the form of a roll of tape of sufficient length to provide multiple tape segments adequate to provide a prescribed dosage of said pharmacologically-active agent.
15. A device for the controlled release and transdermal delivery of a pharmcologically-active agent comprising, a solid vinyl plastisol layer comprising by weight from about 30 up to about 50% of a polyvinyl chloride resin; from about 20 up to about 70% of a plasticizer and from about 0.5 up to about 35% of a pharmacologically-active agent which, when a surface of said layer is in contact with the skin of an animal to be treated with said pharmacologically-active agent, is absorbed into and through skin and thence into the circulatory system of said animal, said pharmacologically-active agent being uniformly dispersed in said plastisol layer in an amount such that an effective amount of the pharmacologically-active agent is absorbed through the skin of said animal in a prescribed period of time, a backing layer covering the surface of said plastisol layer opposite the skin contacting surface of said plastisol layer, said backing layer forming a barrier substantially blocking release of said pharmacologically-active agent from the surface of said plastisol layer opposite the skin contacting surface, and means for maintaining the skin contacting surface of said plastisol layer in contact with the skin of said animal so that transdermal absorption of said pharmacologically-active agent takes place.
16. The device of claim 15 wherein a rate controlling membrane is attached to the plastisol layer on the side of the plastisol layer opposite to the backing layer.
17. .[.An article.]. .Iadd.The device .Iaddend.of claim 15 or 16 wherein the means for maintaining the skin contacting surface of said plastisol layer in contact with the skin is a pressure sensitive adhesive adhered to the plastisol layer on the side of the plastisol layer opposite said backing layer.
18. .[.An article.]. .Iadd.The device .Iaddend.of claim 15 or 16 wherein the means for maintaining the skin contacting surface of said plastisol layer in contact with the skin is a pressure sensitive adhesive layer adhered to the side of the backing layer opposite the plastisol layer and extending beyond the periphery of the plastisol layer.
19. The device of claim 15 or 16 wherein said plasticizer is a polymeric plasticizer or a monomeric plasticizer.
20. The .[.article.]. .Iadd.device .Iaddend.of claim 19 wherein the polymeric plasticizer is a polyphthalate.[.having the IR spectrum of FIG. 12.]..
21. The .[.article.]. device of claim 19 wherein the plasticizer is dioctyl phthalate.
22. The .[.article.]. device of claim 19 wherein the polymeric plasticizer is epoxidized soybean oil.
23. The device of claim 15 or 16 wherein said polyvinyl chloride is present in an amount of about .Badd.30-50%, said plasticizer is present in an amount of about 30-60, and said pharmacologically-active agent is present in an amount of about 0.5-35%.
24. The device of claim 17 in the form of an elongated tape.
25. The device of claim 24 wherein the plasticizer is a polymeric plasticizer.
26. The device of claim 25 wherein said polyvinyl chloride is present in an amount of about 30-50%, said plasticizer is present in an amount of about 30-60%, and said pharmacologically-active agent is present in am amount of about 0.5-35%.
27. The device of claim 24 wherein said tape is provided with indicia indicating the length of a segment of said tape which is adequate to administer a prescribed dosage of said pharmacologically-active agent.
28. The device of claim 24 in the form of a roll of tape of sufficient length to provide multiple tape segments adequate to provide a prescribed dosage of said drug.
29. The .[.article of manufacture.]. .Iadd.device .Iaddend.of claim 1 wherein the plasticizer is the compound having the structure: ##STR27##
30. The .[.article of manufacture.]. .Iadd.device .Iaddend.of claim 1 wherein the plasticizer is N,N-diethyltoluaminde.
31. The .[.article.]. .Iadd.device .Iaddend.of claim 2 or 16 wherein the rate controlling membrane comprises an ethylene-methyl acrylate copolymer having 2-90% by weight of methyl acrylate monomeric units. .Iadd.32. The device of claim 11 wherein the pharmacologically-active agent is nitroglycerin and the nitroglycerin is present in an amount of about 8.0-10%. .Iaddend. .Iadd.33. The device of claim 3 wherein the polyermic plasticizer is a polyadipate. .Iaddend. .Iadd.34. The device of claim 19 wherein the polymeric plastizicer is a polyadipate. .Iaddend.
US07/554,499 1984-10-05 1990-07-19 Article useful for administration of pharmacologically-active substances transdermally, orally, or by means of implant Expired - Lifetime USRE34089E (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US07/554,499 USRE34089E (en) 1984-10-05 1990-07-19 Article useful for administration of pharmacologically-active substances transdermally, orally, or by means of implant

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65791184A 1984-10-05 1984-10-05
US06/847,635 US4758434A (en) 1984-10-05 1986-04-03 Article useful for administration of pharmacologically-active substances transdermally, orally, or by means of implant
US07/554,499 USRE34089E (en) 1984-10-05 1990-07-19 Article useful for administration of pharmacologically-active substances transdermally, orally, or by means of implant

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US06/847,635 Reissue US4758434A (en) 1982-09-01 1986-04-03 Article useful for administration of pharmacologically-active substances transdermally, orally, or by means of implant

Publications (1)

Publication Number Publication Date
USRE34089E true USRE34089E (en) 1992-10-06

Family

ID=27382862

Family Applications (2)

Application Number Title Priority Date Filing Date
US07/122,862 Expired - Fee Related US4767808A (en) 1984-10-05 1987-11-19 Article useful for administration of pharmacologically-active substances transdermally, orally, or by means of implant
US07/554,499 Expired - Lifetime USRE34089E (en) 1984-10-05 1990-07-19 Article useful for administration of pharmacologically-active substances transdermally, orally, or by means of implant

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US07/122,862 Expired - Fee Related US4767808A (en) 1984-10-05 1987-11-19 Article useful for administration of pharmacologically-active substances transdermally, orally, or by means of implant

Country Status (1)

Country Link
US (2) US4767808A (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362496A (en) * 1993-08-04 1994-11-08 Pharmetrix Corporation Method and therapeutic system for smoking cessation
US5549906A (en) * 1993-07-26 1996-08-27 Pharmacia Ab Nicotine lozenge and therapeutic method for smoking cessation
US5730721A (en) 1996-01-25 1998-03-24 Vesture Corporation Medical applicator and method
US6562004B1 (en) 2000-06-05 2003-05-13 The Massachusetts General Hospital Transdermal delivery
US20040086552A1 (en) * 2000-07-12 2004-05-06 Karin Klokkers Transdermal therapeutic system for highly dispersed silicon dioxide
US20050142176A1 (en) * 2003-12-31 2005-06-30 Industrial Technology Research Institute Transdermal patch for long-term steady release
US20060075514A1 (en) * 2004-05-21 2006-04-06 Flotte Thomas J Transport across nuclear membranes by impulse transients
US20130245575A1 (en) * 2012-03-14 2013-09-19 Sara Jo Griffin Body product and method of delivery

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE64726B1 (en) * 1987-11-20 1995-08-23 Elan Corp Plc Pharmaceutical formulations for preventing drug tolerance
US4915301A (en) * 1988-11-15 1990-04-10 International Flavors & Fragrances, Inc. Container with sorbent member and microporous membrane for dispensing vapor from volatile liquid
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
US20040029959A1 (en) * 2002-08-08 2004-02-12 John Devane Isosorbide mononitrate compositions and methods of their use
CN111491953B (en) * 2017-11-14 2022-12-23 艾利丹尼森公司 PVC compositions, films, laminates, and related methods

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH288880A (en) * 1949-09-10 1953-02-15 Werman Jacques Hygienic packaging for dressings and the like.
US3212495A (en) * 1962-06-22 1965-10-19 Hazleton Lab Inc Sensitivity test patches
CA930668A (en) * 1969-04-01 1973-07-24 Zaffaroni Alejandro Bandage for administering drugs
US4150109A (en) * 1974-05-07 1979-04-17 Dick Pierre R G Devices for protecting animals from ectoparasites
US4340530A (en) * 1977-12-08 1982-07-20 Sumitomo Bakelite Company Limited Vinyl chloride type resin composition
US4699777A (en) * 1985-08-21 1987-10-13 Schering Corporation Compositions and method for enhancement of the transdermal flux of albuterol with a combination of 1-dodecyl-azacyclopheptan-2-one and urea

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE497653A (en) * 1949-08-18
US2548433A (en) * 1949-10-12 1951-04-10 Heyden Chemical Corp Plastisols containing nitrogenous viscosity controlling agents
US3326839A (en) * 1963-06-21 1967-06-20 Gulf Research Development Co Plasticized vinyl chloride polymers stabilized with an alkyl diphenylamine

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH288880A (en) * 1949-09-10 1953-02-15 Werman Jacques Hygienic packaging for dressings and the like.
US3212495A (en) * 1962-06-22 1965-10-19 Hazleton Lab Inc Sensitivity test patches
CA930668A (en) * 1969-04-01 1973-07-24 Zaffaroni Alejandro Bandage for administering drugs
US4150109A (en) * 1974-05-07 1979-04-17 Dick Pierre R G Devices for protecting animals from ectoparasites
US4340530A (en) * 1977-12-08 1982-07-20 Sumitomo Bakelite Company Limited Vinyl chloride type resin composition
US4699777A (en) * 1985-08-21 1987-10-13 Schering Corporation Compositions and method for enhancement of the transdermal flux of albuterol with a combination of 1-dodecyl-azacyclopheptan-2-one and urea

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5549906A (en) * 1993-07-26 1996-08-27 Pharmacia Ab Nicotine lozenge and therapeutic method for smoking cessation
US5662920A (en) * 1993-07-26 1997-09-02 Pharmacia Ab Nicotine lozenge and therapeutic method for smoking cessation
US6280761B1 (en) 1993-07-26 2001-08-28 Pharmacia Ab Nicotine lozenge
US5362496A (en) * 1993-08-04 1994-11-08 Pharmetrix Corporation Method and therapeutic system for smoking cessation
US5730721A (en) 1996-01-25 1998-03-24 Vesture Corporation Medical applicator and method
US6562004B1 (en) 2000-06-05 2003-05-13 The Massachusetts General Hospital Transdermal delivery
US20040086552A1 (en) * 2000-07-12 2004-05-06 Karin Klokkers Transdermal therapeutic system for highly dispersed silicon dioxide
US20050142176A1 (en) * 2003-12-31 2005-06-30 Industrial Technology Research Institute Transdermal patch for long-term steady release
US20060075514A1 (en) * 2004-05-21 2006-04-06 Flotte Thomas J Transport across nuclear membranes by impulse transients
US20130245575A1 (en) * 2012-03-14 2013-09-19 Sara Jo Griffin Body product and method of delivery

Also Published As

Publication number Publication date
US4767808A (en) 1988-08-30

Similar Documents

Publication Publication Date Title
US4758434A (en) Article useful for administration of pharmacologically-active substances transdermally, orally, or by means of implant
US5310559A (en) Device for controlled release and delivery to mammalian tissue of pharmacologically active agents incorporating a rate controlling member which comprises an alkylene-alkyl acrylate copolymer
US4792450A (en) Device for controlled release drug delivery
US5322695A (en) Moisture-vapor-permeable dressing
EP0316065B1 (en) Improved transdermal drug delivery device
US5411740A (en) Transdermal administration of oxybutynin
US4837027A (en) Transdermal drug delivery device
US5614211A (en) Oxybutynin transdermal device having decreased delamination
US5834010A (en) Triacetin as a penetration enhancer for transdermal delivery of a basic drug
USRE34089E (en) Article useful for administration of pharmacologically-active substances transdermally, orally, or by means of implant
Sugibayashi et al. Polymers for transdermal drug delivery systems
JPH0430372B2 (en)
US5468501A (en) Article useful for administration of pharmacologically-active substances transdermally, orally or by means of implant
US4765986A (en) Medicinal plaster for systemic use
KR960005148B1 (en) Transdermal system exhibiting graduated drug release
EP0251425B1 (en) Article for administration of pharmacologically-active substances
CA1309661C (en) Transdermal delivery system
US4931281A (en) Laminar structure for administering a chemical at a controlled release rate
US5176917A (en) Transdermal system exhibiting graduated drug release and its use for the local or systemic administration of active substances
JPH02149514A (en) medical parts
EP0274863B1 (en) Moisture-vapor-permeable dressing
US5002773A (en) Transdermal delivery of (+) (2S,3S)-3-acetoxy-8-chloro-5-(2-dimethylaminoethyl)-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4-(5H)-one
JP2781016B2 (en) Transdermal formulation
JP2527934B2 (en) Patch
JPS62289514A (en) Product for administrating pharmacological substance transdermally, orally or by hypodermic implantation

Legal Events

Date Code Title Description
AS Assignment

Owner name: FIRST NATIONAL BANK OF MARYLAND, THE, MARYLAND

Free format text: SECURITY INTEREST;ASSIGNOR:HERCON LABORATORIES CORPORATION, A DELAWARE CORPORATION;REEL/FRAME:007122/0705

Effective date: 19940715

AS Assignment

Owner name: FIRST NATIONAL BANK OF MARYLAND, THE, MARYLAND

Free format text: SECURITY AGREEMENT;ASSIGNOR:HERCON LABORATORIES CORPORATION;REEL/FRAME:007696/0003

Effective date: 19951011

FEPP Fee payment procedure

Free format text: PAT HOLDER CLAIMS SMALL ENTITY STATUS - SMALL BUSINESS (ORIGINAL EVENT CODE: SM02); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FPAY Fee payment

Year of fee payment: 8

AS Assignment

Owner name: HERCON LABORATORIES CORPORATION, NEW YORK

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:FIRST NATIONAL BANK OF MARYLAND, THE;REEL/FRAME:008313/0668

Effective date: 19970109

Owner name: HERCON LABORATORIES CORPORATION, NEW YORK

Free format text: RELEASE AND REASSIGNMENT OF PATENTS AS COLLATERAL;ASSIGNOR:FIRST NATIONAL BANK OF MARYLAND, THE;REEL/FRAME:008313/0672

Effective date: 19970109

AS Assignment

Owner name: IBM SCHRODER BANK & TRUST COMPANY, AS AGENT, NEW Y

Free format text: SECURITY AGREEMENT;ASSIGNOR:HERCON LABORATORIES CORPORATION;REEL/FRAME:008470/0075

Effective date: 19970109

Owner name: IBJ SCHRODER BANK & TRUST COMPANY, AS AGENT, NEW Y

Free format text: SECURITY INTEREST;ASSIGNOR:HEROON LABORATORIES CORPORATION;REEL/FRAME:008470/0567

Effective date: 19970109

AS Assignment

Owner name: HERCON LABORATORIES CORPORATION, NEW YORK

Free format text: PATENT RE-ASSIGNMENT AND RELEASE OF SECURITY AGREEMENT;ASSIGNOR:IBJ WHITEHALL BUSINESS CREDIT CORPORATION, (F/K/A IBJ SCHRODER BUSINESS CREDIT CORPORATION, AS SUCCESSOR IN INTEREST TO IBJ SCHRODER BANK & TRUST COMPANY);REEL/FRAME:010197/0675

Effective date: 19990817